PKD2, mutations in which cause autosomal dominant polycystic kidney disease 1 (ADPKD),
encodes an integral membrane glycoprotein 2 with similarity to calcium channel subunits 1 …

Objectives To compare efficacy and safety of sarilumab monotherapy with adalimumab
monotherapy in patients with active rheumatoid arthritis (RA) who should not continue …

Objective To evaluate the efficacy and safety of sarilumab in combination with methotrexate
(MTX) for the treatment of rheumatoid arthritis (RA). Methods Adults with moderate‐to …

Objectives To evaluate safety and efficacy of weekly (qw) and every other week (q2w)
dosing of sarilumab, a fully human anti-interleukin 6 receptor α (anti-IL-6Rα) monoclonal …

Objective: To investigate the effects of continued use of non-selective NSAIDs (nsNSAIDs)
on blood pressure and hypertension. Research design and methods: This was a systematic …

Objective To evaluate the efficacy and safety of sarilumab plus conventional synthetic
disease‐modifying antirheumatic drugs (DMARDs) in patients with active moderate‐to …

Autosomal dominant polycystic kidney disease (ADPKD) is a common human genetic
disease characterized by cyst formation in kidney tubules and other ductular epithelia. Cells …

BACKGROUND: Symptoms of allergic rhinitis are mediated in part by cysteinyl leukotrienes.
OBJECTIVES: To evaluate the clinical benefit of montelukast, a cysteinyl leukotriene …

BACKGROUND: Montelukast, a potent leukotriene receptor antagonist, is an effective
therapy for symptoms of seasonal allergic rhinitis, a disease governed by patients' individual …

BACKGROUND: Leukotriene modifiers have been shown to protect against exercise-
induced bronchoconstriction (EIB) with repeated, chronic dosing. OBJECTIVE: To study the …